Alder Biopharmaceuticals, Inc.

Amgen, Inc. ’s products in highly competitive spaces, such as rheumatoid arthritis and migraine, experienced sales volume declines in the fourth quarter, contributing to a Q4 revenue total that fell b

It appears that the COVID-19 pandemic largely has not had a big impact on sales of novel migraine therapies, except for the one new product that can’t be administered by patients at home. In fact, wit

Lundbeck Inc. struck a positive note when describing the approval and launch of its much-anticipated new migraine therapy, Vyepti (eptinezumab-jjmr), in the US in the first quarter, saying the drug h

Lundbeck Inc. does not see the intravenous administration of its newly approved migraine prevention therapy Vyepti (eptinezumab-jjmr) as a hurdle to commercial success despite the availability of thr